INSR and neoplasm: OSI-906 (Astellas Pharma Inc., Tokyo, Japan) is a potent, selective, orally bioavailable, dual IGF1R/INSR TKI, which has demonstrated in vivo efficacy in tumor models and is currently in clinical evaluation.